Skip to main content
Christopher da Costa, MD, Internal Medicine, Furlong, PA

ChristopherThomasda CostaMDPhD, MBA, FACP, FIDSA, CWSP, CPE

Internal Medicine Furlong, PA

Hospital Medicine/Hospitalist, Preventive Medicine, Infectious Disease

Physician-scientist, Immunologist, Internal Medicine, infectious Diseases, Wound Care, Hyperbaric Medicine, Vaccine development, Therapeutic and Immunoprophylactic drug development. Takemi Fellow in International Health. Harvard T. H. Chan School of Public Health.

Dr. da Costa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. da Costa's full profile

Already have an account?

  • Office

    Furlong
    Furlong, PA 18925
    Phone+1 267-406-2485

Summary

  • US licensed and board-certified physician with over 20 years' experience in clinical medicine and over 15 years total of clinical and basic science research experience, including phase I-IV clinical development, medical affairs, health economics & outcomes research, regulatory affairs, and strategic leadership of clinical development teams. Expertise spans vaccine and small molecule clinical research and development, including efficacy, safety, and effectiveness studies for prophylactic pediatric vaccines, as well as expertise in strategic development planning in therapeutic vaccinology, including monoclonal antibody-based active and passive immunotherapy. Therapeutic area experience includes vaccines, infectious diseases, neuroscience, hematology, organ transplantation, and immunology. Clinical experience includes internal medicine, infectious diseases, wound care/ esthetic and hyperbaric medicine. Fellow American College of Physicians, Fellow Infectious Disease Society of America. Certified Wound Specialist Physician. Dr. da Costa was appointed to the staff of the Harvard T.H. Chan School of Public Health in August 2023 as a Takemi International Health Fellow.

Education & Training

  • Harvard School of Public Health
    Harvard School of Public HealthFellowship, 2023 - 2024
  • Harvard Medical School
    Harvard Medical SchoolGlobal Health, Global Health Care Leaders Program, 2021 - 2022
  • Wharton School, University of Pennsylvania
    Wharton School, University of PennsylvaniaEntrepreneurial Acceleration Program, Executive education (Business), 2019 - 2019
  • Auburn University
    Auburn UniversityMBA, Physician's Executive MBA, 2001 - 2003
  • Kirk Kerkorian School of Medicine at UNLV
    Kirk Kerkorian School of Medicine at UNLVChief Residency, Internal Medicine, 1998 - 1999
  • Kirk Kerkorian School of Medicine at UNLV
    Kirk Kerkorian School of Medicine at UNLVResidency, Internal Medicine, 1996 - 1998
  • London School of Hygiene & Tropical Medicine
    London School of Hygiene & Tropical MedicinePhD, Immunology (Infectious Diseases), 1987 - 1991
  • London School of Hygiene & Tropical Medicine
    London School of Hygiene & Tropical MedicineMSc., Clinical Tropical Medicine, 1985 - 1986
  • University of Zambia, School of Med
    University of Zambia, School of MedClass of 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2018 - 2026
  • PA State Medical License
    PA State Medical License 2007 - 2024
  • NC State Medical License
    NC State Medical License 2011 - 2016
  • VA State Medical License
    VA State Medical License 2000 - 2016
  • CA State Medical License
    CA State Medical License 2011 - 2014
  • American Board of Internal Medicine Internal Medicine
  • AAPLCertification in Medical Management (CPE)
  • American Board of Wound ManagementCertified Wound Specialist Physician

Awards, Honors, & Recognition

  • Fellow American College of Physicians
  • Fellow Infectious Disease Society of America
  • Best Internal Medicine Resident, Ambulatory Clinic University of Nevada School of Medicine, 1998-1999
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Perspectives on Advancement and Development of Tuberculosis Vaccines  
    Christopher da Costa, Christine S. Benn, Thomas Nyirenda, Evans Mpabalwani, Harleen M.S. Grewal, Rizwan Ahmed, Nathan Kapata, Peter S. Nyasulu, Markus Maeurer, David S..., International Journal of Infectious DIseases, 2/25/2024
  • End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income ...  
    Eskild Petersen, David S. Hui, Jean B. Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Ch..., International Journal of Infectious DIseases, 4/6/2023
  • SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study  
    John Kokai-Kun, PhD, Tracey Roberts, BSN, Olivia Coughlin, PhD, Heidi Whalen, MHS, Charles Le, PhD, Christopher Da Costa, MD, PhD and Joseph Sliman, MD, PhD, Open Forum Infect Dis. 2017 Fall; 4(Suppl 1): S12. Published online 2017 Oct 4. doi: 10.1093/ofid/ofx162.029 PMCID: PMC5631845, 2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Immunogenicity of GlaxoSmithKline Biologicals, MMR Vaccine vs M-M-R® II, when Co-administered with Hepatitis A, Varicella and Pneumococcal Conjugate Vaccines to Toddle...
    da Costa, C, https://idsa.confex.com/idsa/2011/webprogram/Paper31923.html, 10/21/2011
  • Efficacy of Two-dose MMRV and One-dose Varicella Vaccination in Children Aged 12-22 Months in 10 European Countries
    da Costa, C, http://www.kenes.com/espid2010/posters/Abstract619.htm, 5/4/2010
  • Immunogenicity of one dose of Varicella vaccine and two doses of MMRV vaccine.
    da Costa, C, http://www.kenes.com/espid2010/posters/Abstract558.htm, 5/4/2010
  • Join now to see all

Lectures

  • Strengthening local supply chains, manufacturing & innovation for novel vaccines 
    University of Miami Global Health Program - 2/27/2024
  • CEPI: New vaccines for a safer world 
    Massachussetts General Hospital/Harvard University - 10/2/2023
  • COVID-19 – New Variants and Long COVID 
    National Medical Assocociation- Task Force on Vaccines and Therpeutics - 2/4/2023
  • Join now to see all

Other

Authored Content

  • Advances in Development of New Tuberculosis VaccinesMay 2023

Press Mentions

  • Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica Soni
    Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica SoniOctober 18th, 2016
  • COVID-19 Alumni Stories: Christopher da Costa
    COVID-19 Alumni Stories: Christopher da CostaJuly 19th, 2020

Grant Support

  • Research Initiative Fund GrantUniversity of Wales College of Medicine1993–1995
  • Beit Memorial Medical Research Fellowship GrantBeit Trust1987–1991

Research History

  • Physician Reviewer (Consultant)Physician Reviewer for FDA Biologics Safety and Effectiveness Program for Vaccine and Blood Transfusion Products2019 - Present
  • Consultant, Vedanta BiosciencesMIcrobiome Therapeutics for the prevention of recurrent Clostridium difficile Infection, using Bacterial Consortia2018 - 2019
  • Consultant, Intarcia Therapeutics, Boston, MAClinical Development and Pharmacovigilance for a Drug-Device combination product for use in Glycemic Control in Diabetes Mellitus.2018 - 2019
  • Vice President of Clinical Development, Synthetic BiologicsClinical research and development of a first-in-class agent for the prevention of Clostridium difficile infection, and of a novel therapy for Irritable Bowel Syndrome with constipation (IBS-C).2017 - 2017
  • Global Medical Director, Asahi Kasei Pharma AmericaClinical development of recombinant thrombomodulin as a novel therapy for patients with sepsis, and for the prevention of early allograft dysfunction in liver transplant patients.2015 - 2017
  • Director of Clinical Development, Tuberculosis Vaccines, AerasClinical research and development of TB vaccines.2014 - 2015
  • Senior Medical Director, Pfizer Infectious DiseasesPhase IV clinical research on antibiotics Vancomycin and Linezolid.2011 - 2013
  • Compound Development Team Leader, Janssen Alzheimer Immunotherapy R&D, LLCClinical research on active and passive Immunotherapy for Alzheimer's disease.2010 - 2011
  • Director, Clinical Development and Medical Affairs, GlaxoSmithKline VaccinesClinical research and development of MMR and Varicella vaccines.2006 - 2010
  • Associate Director, Worldwide Regulatory Affairs, Merck and Co.Clinical research on Measles, Mumps, Rubella and Varicella vaccines.2005 - 2006
  • Clinical Lecturer and Research Fellow in Tropical MedicineResearch on immunology of tuberculosis in the context of HIV infection, at the London School of Hygiene & Tropical Medicine.1987 - 1991

Professional Memberships

Other Languages

  • French, Creole